Virios Therapeutics, Inc. (NASDAQ:VIRI – Get Free Report) was down 1.5% during trading on Thursday . The company traded as low as $5.82 and last traded at $5.96. Approximately 52,000 shares traded hands during mid-day trading, a decline of 95% from the average daily volume of 1,049,645 shares. The stock had previously closed at $6.05.
Virios Therapeutics Stock Performance
The company has a market cap of $108.62 million, a price-to-earnings ratio of -20.89 and a beta of 1.58. The company’s fifty day moving average is $7.60 and its two-hundred day moving average is $4.23.
Virios Therapeutics Company Profile
Virios Therapeutics, Inc, a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.
Further Reading
- Five stocks we like better than Virios Therapeutics
- What is the NASDAQ Stock Exchange?
- MarketBeat Week in Review – 03/24 – 03/28
- Are Penny Stocks a Good Fit for Your Portfolio?
- Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low
- Quiet Period Expirations Explained
- 4 Healthcare Stocks With Massive Gains—and More to Come
Receive News & Ratings for Virios Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virios Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
